Is Entrada Therapeutics, Inc. (TRDA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 10.6% / 30% | 61.4% / 30% | 0.2% / 30% | 59.29% / 5% | ✗ NOT HALAL |
| DJIM | 10.6% / 33% | 61.4% / 33% | 0.2% / 33% | 59.29% / 5% | ✗ NOT HALAL |
| MSCI | 13.5% / 33% | 78.4% / 33% | 0.3% / 33% | 59.29% / 5% | ✗ NOT HALAL |
| S&P | 10.6% / 33% | 61.4% / 33% | 0.2% / 33% | 59.29% / 5% | ✗ NOT HALAL |
| FTSE | 13.5% / 33% | 78.4% / 33% | 0.3% / 50% | 59.29% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -3103.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -39.1% | |
| Return on Assets (ROA) | -21.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$129M |
| Free Cash Flow | -$130M |
| Total Debt | $51M |
| Debt-to-Equity | 16.6 |
| Current Ratio | 12.5 |
| Total Assets | $377M |
Price & Trading
| Last Close | $12.31 |
| 50-Day MA | $11.64 |
| 200-Day MA | $8.41 |
| Avg Volume | 225K |
| Beta | -0.1 |
|
52-Week Range
$4.93
| |
About Entrada Therapeutics, Inc. (TRDA)
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Entrada Therapeutics, Inc. (TRDA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Entrada Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Entrada Therapeutics, Inc.'s debt ratio?
Entrada Therapeutics, Inc.'s debt ratio is 10.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 13.5%.
What are Entrada Therapeutics, Inc.'s key financial metrics?
Entrada Therapeutics, Inc. has a market capitalization of $457M, and revenue of $25M. Return on equity stands at -39.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.